It ain't over 'til the fat lady sings

Science Translational Medicine

Volumn 4, Issue 148, 2012, Pages

  Ofermanns, Stefan ^a  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; CHOLESTEROL ESTER TRANSFER PROTEIN; FATTY ACID; FUMARIC ACID ETHYL ESTER; GPR 109A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADIPOCYTE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; BURNING SENSATION; DISEASE COURSE; DRUG MEGADOSE; DYSLIPIDEMIA; FATTY ACID SYNTHESIS; HEART INFARCTION; HOT FLUSH; HUMAN; IMMUNOCOMPETENT CELL; ISCHEMIC HEART DISEASE; LIPOLYSIS; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SHORT SURVEY; SKIN REDNESS; SKIN TINGLING;

ANIMALS; FATTY ACIDS; HUMANS; MALE; NIACIN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC;

EID: 84865341762     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004445     Document Type: Short Survey

References (10)

1. L. A. Carlson, Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258, 94-114 (2005).
2. B. Lauring, A. K. P. Taggart, J. R. Tata, R. Dunbar, L. Caro, K. Cheng, J. Chin, S. L. Colletti, J. Cote, S. Khalilieh, J. Liu, W.-L. Luo, A. A. MacLean, L. B. Peterson, A. B. Polis, W. Sirah, T.-J. Wu, X. Liu, L. Jin, K. Wu, P. D. Boatman, G. Semple, D. P. Behan, D. T. Connolly, E. Lai, J. A. Wagner, S. D. Wright, C. Cuffie, Y. B. Mitchel, D. J. Rader, J. F. Paolini, M. G. Waters, A. Plump, Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci. Transl. Med. 4, 148ra115 (2012).
3. A. Gille, E. T. Bodor, K. Ahmed, S. Oflermanns, Nicotinic acid: Pharmacological eflects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol. 48, 79-106 (2008).
4. S. Lamon-Fava, M. R. Diflenderfer, P. H. Barrett, A. Buchsbaum, M. Nyaku, K. V. Horvath, B. F. Asztalos, S. Otokozawa, M. Ai, N. R. Matthan, A. H. Lichtenstein, G. G. Dolnikowski, E. J. Schaefer, Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler. Thromb. Vasc. Biol. 28, 1672-1678 (2008).
5. C. Hernandez, M. Molusky, Y. Li, S. Li, J. D. Lin, Regulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic eflect of nicotinic acid. Cell Metab. 12, 411-419 (2010).
6. V. S. Kamanna, S. H. Ganji, M. L. Kashyap, Niacin: An old drug rejuvenated. Curr. Atheroscler. Rep. 11, 45-51 (2009).
7. A. G. Olsson, Is high HDL cholesterol always good? Ann. Med. 41, 11-18 (2009).
8. M. Lukasova, J. Hanson, S. Tunaru, S. Oflermanns, Nicotinic acid (niacin): New lipid-independent mechanisms of action and therapeutic potentials. Trends Pharmacol. Sci. 32, 700-707 (2011).
9. M. Lukasova, C. Malaval, A. Gille, J. Kero, S. Oflermanns, Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J. Clin. Invest. 121, 1163-1173 (2011).
10. W. E. Boden, J. L. Probstfield, T. Anderson, B. R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, W. Weintraub, AIM-HIGH Investigators, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255-2267 (2011).